{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lacerations/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"23d49e6f-7a37-5188-8b3f-6b6fdb671019","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 9aa34811-4994-46d4-9dc2-1c6301d10f11 --><h2>Metronidazole</h2><!-- end field 9aa34811-4994-46d4-9dc2-1c6301d10f11 -->","summary":"","htmlStringContent":"<!-- begin item 13cca021-32f2-43bc-bf1f-cc5ff4aca2a3 --><!-- end item 13cca021-32f2-43bc-bf1f-cc5ff4aca2a3 -->","topic":{"id":"bc1075da-03fb-510a-aafc-42f8402c77bb","topicId":"c455b3ad-86f5-4c2b-a00d-ceb66ba46f46","topicName":"Lacerations","slug":"lacerations","lastRevised":"Last revised in January 2021","chapters":[{"id":"abcb9c5e-8c70-578e-b2f1-2bfe9e0e6dea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b3295eac-08d7-597e-9bbf-240c812490a5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0f6da996-76f9-5508-aead-4f7d04fc2910","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3713be7a-1d15-503e-9cdb-6d3afe60f335","slug":"changes","fullItemName":"Changes"},{"id":"d164a0e0-2763-5ec6-8aaa-1f68fe1d381c","slug":"update","fullItemName":"Update"}]},{"id":"e6d917bb-ce9e-58a6-8b13-cf3e389a6aef","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"83820372-5bd1-5e60-a139-cd76615ac683","slug":"goals","fullItemName":"Goals"},{"id":"15606cb7-089f-5a7d-af3f-d4b9c9b0d2be","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1a9aa28b-0708-5c58-843c-05a09196b471","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"682e483f-7847-5e82-be10-969f896d9533","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0db2153f-bcb4-5382-9178-92d651a01c4e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3929f359-184e-53d4-8aca-a4081b967c1a","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"313e7f7d-a625-5b48-a31d-e5f00ca31462","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0ad26899-0f07-5523-8ea6-17d520df4cc8","slug":"definition","fullItemName":"Definition"},{"id":"e917af1e-ca7f-5ddd-9cb9-1132ce21b4a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe57a056-8e82-56fa-bb79-87f037fb4303","slug":"complications","fullItemName":"Complications"}]},{"id":"e01eac70-aab4-50c3-a90e-7b07194bf1c8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c1be68cd-346e-504f-b22f-e8352fc5c3f6","slug":"assessment","fullItemName":"Assessment"}]},{"id":"35a250d2-9a3b-5287-8afa-d73dfc12c39b","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c6adc10-cc7f-5820-b2da-874e89c9b72b","slug":"laceration-low-infection-risk","fullItemName":"Scenario: Laceration - low infection risk"},{"id":"496fa19f-131c-5dd3-8be3-ae041478b608","slug":"laceration-high-infection-risk","fullItemName":"Scenario: Laceration - high infection risk"},{"id":"9204ec1a-d022-5955-9f74-6b4eb51bf9a9","slug":"laceration-infected","fullItemName":"Scenario: Laceration - infected"}]},{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ffdfa8df-e6e7-56b4-99c6-dfe62dda65a2","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f4667375-a12d-57c4-a82a-192c500b41bb","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"8d7c7214-71fc-5171-9875-f310b20c40cb","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"23d49e6f-7a37-5188-8b3f-6b6fdb671019","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f3f77580-8498-590e-a7c3-0afbee563567","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8f912e41-1ff8-5fce-b9b4-6b3524e8f79b","slug":"tetanus-booster","fullItemName":"Tetanus booster"}]},{"id":"b1fc897d-bfab-5305-bcf1-70e0f4598e5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"18a38028-bff4-54de-948c-9715f3649589","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0132c748-edac-513b-a351-59a838b07e61","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b4b28cd4-4652-528e-aa28-23f341c6a31e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b86d931b-dadb-55a7-92c8-6cdb81ce5d7f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6695afc-2f21-5bf7-907b-68a0fb3a77c4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d4ab79d3-d601-5b9b-b2b5-d3256e138671","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc9ca4ec-c56f-5acc-830c-ccf5c31d5f67","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"4a5c9859-de5e-52e7-bbc7-f96cc37a6ebe","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field af537325-b296-4efe-9e25-a76801671a1e --><h3>What are the licensed doses of metronidazole?</h3><!-- end field af537325-b296-4efe-9e25-a76801671a1e -->","summary":"","htmlStringContent":"<!-- begin item 634a1dd5-31dc-49da-ae78-a768016717a8 --><!-- begin field 3811e302-9ecd-4846-abfe-a76801671a1e --><ul><li><strong>Prescribe metronidazole for 5–7 days. The licensed oral does are:</strong><ul><li><strong>Children aged 1 month </strong>— 7.5 mg/kg every 12 hours.</li><li><strong>Children aged 2 months to 11 years </strong>— 7.5 mg/kg every 8 hours (maximum of 400 mg per dose).</li><li><strong>Children aged 12 years to 17 years </strong>— 400 mg every 8 hours.</li><li><strong>Adults </strong>— 400 mg every 8 hours <em>or</em> 500 mg every 8 hours.</li></ul></li><li><strong>In severe hepatic impairment, </strong>reduce total daily dose to one-third, and give once daily.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF for Children, 2017</a>]</p><!-- end field 3811e302-9ecd-4846-abfe-a76801671a1e --><!-- end item 634a1dd5-31dc-49da-ae78-a768016717a8 -->","subChapters":[]},{"id":"db1afa8d-c036-5302-a3fe-04abf22c52c1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b704795c-85d2-49a0-a2b1-a7680167322a --><h3>What are the contraindications and cautions for metronidazole?</h3><!-- end field b704795c-85d2-49a0-a2b1-a7680167322a -->","summary":"","htmlStringContent":"<!-- begin item 461709ac-cb14-4fdb-b2ed-a7680167306c --><!-- begin field 44893617-e281-453c-9a3d-a7680167322f --><ul><li><strong>Do not prescribe metronidazole to a person with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li><li>Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories). For people with Cockayne syndrome specialist advice should therefore be sought before prescribing metronidazole. </li></ul></li><li><strong>Prescribe metronidazole with caution</strong><strong> in:</strong><ul><li><strong>People with:</strong><ul><li>Active or chronic severe peripheral and central nervous system disease (due to the risk of neurological aggravation).</li><li>Severe liver disease and hepatic encephalopathy (due to substantial impairment of metronidazole clearance) — reduce the total daily <a class=\"topic-reference internal-reference\" href=\"/topics/lacerations/prescribing-information/metronidazole/#licensed-doses\">dose</a> to one-third, and give once daily.</li></ul></li><li><strong>Pregnant women </strong>— the manufacturer states that although there is inadequate evidence of the safety of metronidazole in pregnancy, it has been widely used for many years without apparent ill consequence. However, high-dose regimens should be avoided.</li><li><strong>Breastfeeding women </strong>— a significant amount of metronidazole is excreted in breast milk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>]. The manufacturer advises that high-dose regimens should be avoided during breastfeeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>]</p><!-- end field 44893617-e281-453c-9a3d-a7680167322f --><!-- end item 461709ac-cb14-4fdb-b2ed-a7680167306c -->","subChapters":[]},{"id":"9da30813-0793-5e20-b0a2-834a375c1503","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f36c4dd4-930d-46aa-bfe4-a768016742b8 --><h3>What are the possible adverse effects of metronidazole?</h3><!-- end field f36c4dd4-930d-46aa-bfe4-a768016742b8 -->","summary":"","htmlStringContent":"<!-- begin item 729445f3-a244-4858-90c0-a768016740f6 --><!-- begin field 4ba04a86-282e-497d-b337-a768016742b8 --><ul><li><strong>Adverse effects of metronidazole include </strong>gastrointestinal disturbances (including nausea and vomiting), taste disturbances, furred tongue, oral mucositis, and anorexia.</li><li><strong>Very rarely, the following may occur: </strong>hepatitis, jaundice, pancreatitis, drowsiness, dizziness, headache, convulsion, ataxia, psychotic disorders (including confusion and hallucinations), darkening of urine, thrombocytopenia, pancytopenia, myalgia, arthralgia, visual disturbances, rash, pruritus, and erythema multiforme.<ul><li>Advise the person not to drive or operate machinery if drowsiness, dizziness, confusion, hallucinations, convulsions, or transient visual disturbances occur.</li></ul></li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>]</p><!-- end field 4ba04a86-282e-497d-b337-a768016742b8 --><!-- end item 729445f3-a244-4858-90c0-a768016740f6 -->","subChapters":[]},{"id":"c5f81df7-7bf9-51f8-bb4f-e45eb4c62a5c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 033c9b8d-06ac-4d9d-8bfa-a76801675300 --><h3>What drug interactions are associated with metronidazole?</h3><!-- end field 033c9b8d-06ac-4d9d-8bfa-a76801675300 -->","summary":"","htmlStringContent":"<!-- begin item 1c96dbb2-8162-43c4-bba0-a76801675148 --><!-- begin field 8e0737f8-1275-4313-911d-a76801675300 --><ul><li><strong>Drug interactions associated with oral metronidazole include:</strong><ul><li><strong>Alcohol </strong>— some people taking oral metronidazole experience a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) with alcohol.<ul><li>Although there is no conclusive evidence to support this interaction, warn the person that they <em>might</em> experience this reaction if they drink alcohol whilst taking metronidazole. Alcohol should be avoided during treatment with metronidazole and for at least 48 hours afterwards.</li></ul></li><li><strong>Anticoagulants </strong>— the anticoagulant effects of warfarin can be markedly increased by metronidazole.<ul><li>Monitor the international normalized ratio (INR) if metronidazole is given with warfarin, and adjust the warfarin dose accordingly.</li><li>Warn the person of the possible risk of increased bruising and bleeding, and advise them on when to seek medical help.</li></ul></li><li><strong>Ciclosporin </strong>— people receiving ciclosporin are at risk of elevated serum ciclosporin levels.<ul><li>When co-administration of metronidazole and ciclosporin is necessary, monitor serum ciclosporin and creatinine levels closely.</li></ul></li><li><strong>Lithium </strong>— raised lithium levels accompanied by evidence of possible renal damage has been reported in people treated concurrently with lithium and metronidazole.<ul><li>Before starting metronidazole in a person taking lithium, seek specialist advice regarding tapering or stopping lithium treatment. If concurrent treatment is unavoidable, plasma concentrations of lithium, creatinine, and electrolytes should be monitored closely.</li></ul></li></ul></li><li><strong>Oral contraceptives </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of metronidazole.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions of metronidazole</strong><strong>, </strong>see the <a data-hyperlink-id=\"ba4589c2-1c85-47d6-8b22-a98f01899934\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"8b6a4b10-f39b-4e14-a3ba-a98f0189994e\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">FSRH, 2017</a>]</p><!-- end field 8e0737f8-1275-4313-911d-a76801675300 --><!-- end item 1c96dbb2-8162-43c4-bba0-a76801675148 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}